Cargando…
The combined analgesic effect of pregabalin and morphine in the treatment of pancreatic cancer pain, a retrospective study
BACKGROUND: Pregabalin is commonly used to relieve neuropathic pain. However, data are lacking on its efficacy for the treatment of chronic cancer pain. The purpose of this study was to determine the analgesic efficacy of pregabalin combined with morphine in the management of pancreatic cancer pain....
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940217/ https://www.ncbi.nlm.nih.gov/pubmed/33594813 http://dx.doi.org/10.1002/cam4.3779 |
_version_ | 1783661905277091840 |
---|---|
author | Dai, Junzhu Teng, Lei Zhao, Liuyuan Zou, Huichao |
author_facet | Dai, Junzhu Teng, Lei Zhao, Liuyuan Zou, Huichao |
author_sort | Dai, Junzhu |
collection | PubMed |
description | BACKGROUND: Pregabalin is commonly used to relieve neuropathic pain. However, data are lacking on its efficacy for the treatment of chronic cancer pain. The purpose of this study was to determine the analgesic efficacy of pregabalin combined with morphine in the management of pancreatic cancer pain. METHODS: This study reviewed patients who were prescribed morphine and 150 mg/d pregabalin between 1 January 2017 and 10 November 2018 in our institute. The primary outcomes of this study were the average pain score and dose of morphine. Secondary outcomes included characters of breakthrough cancer pain, functional interference related to pain, anxiety/depression status, and incidence of treatment‐related adverse events during the study. RESULTS: A total of 240 patients with pain related to pancreatic cancer were included in the study. The results showed that patients of both combination therapy group (pregabalin+morphine) and monotherapy group (morphine) achieved similar analgesic efficacy, demonstrated by NRS (2.4 ± 0.9 vs. 2.6 ± 0.9; combination vs. monotherapy) at the end of the study. Mean daily dose of morphine used in the combination group was significant lower compared to monotherapy group (39.5 ± 16.0 mg vs. 61.5 ± 19.3 mg, net difference 23.5, 95% CI: 18.4–28.6, p < 0.001). The change of functional interference score related to pain was significantly different between combination and monotherapy group (12.0 ± 0.4 vs. 9.8 ± 4.9; net difference, 2.3; 95% CI: 1.1–3.3; p < 0.001). Patients in combination therapy group had experienced shorter duration of breakthrough cancer pain than those in monotherapy group (X(2) p < 0.001, Cramer's V:0.36). The incidence of somnolence, dizziness, and cognitive dysfunction were significantly higher in the combination group compared to monotherapy group. No serious treatment‐related side effects were observed. CONCLUSIONS: The findings of this study supported the use of pregabalin with morphine to relieve pain in patients of pancreatic cancer. |
format | Online Article Text |
id | pubmed-7940217 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79402172021-03-16 The combined analgesic effect of pregabalin and morphine in the treatment of pancreatic cancer pain, a retrospective study Dai, Junzhu Teng, Lei Zhao, Liuyuan Zou, Huichao Cancer Med Clinical Cancer Research BACKGROUND: Pregabalin is commonly used to relieve neuropathic pain. However, data are lacking on its efficacy for the treatment of chronic cancer pain. The purpose of this study was to determine the analgesic efficacy of pregabalin combined with morphine in the management of pancreatic cancer pain. METHODS: This study reviewed patients who were prescribed morphine and 150 mg/d pregabalin between 1 January 2017 and 10 November 2018 in our institute. The primary outcomes of this study were the average pain score and dose of morphine. Secondary outcomes included characters of breakthrough cancer pain, functional interference related to pain, anxiety/depression status, and incidence of treatment‐related adverse events during the study. RESULTS: A total of 240 patients with pain related to pancreatic cancer were included in the study. The results showed that patients of both combination therapy group (pregabalin+morphine) and monotherapy group (morphine) achieved similar analgesic efficacy, demonstrated by NRS (2.4 ± 0.9 vs. 2.6 ± 0.9; combination vs. monotherapy) at the end of the study. Mean daily dose of morphine used in the combination group was significant lower compared to monotherapy group (39.5 ± 16.0 mg vs. 61.5 ± 19.3 mg, net difference 23.5, 95% CI: 18.4–28.6, p < 0.001). The change of functional interference score related to pain was significantly different between combination and monotherapy group (12.0 ± 0.4 vs. 9.8 ± 4.9; net difference, 2.3; 95% CI: 1.1–3.3; p < 0.001). Patients in combination therapy group had experienced shorter duration of breakthrough cancer pain than those in monotherapy group (X(2) p < 0.001, Cramer's V:0.36). The incidence of somnolence, dizziness, and cognitive dysfunction were significantly higher in the combination group compared to monotherapy group. No serious treatment‐related side effects were observed. CONCLUSIONS: The findings of this study supported the use of pregabalin with morphine to relieve pain in patients of pancreatic cancer. John Wiley and Sons Inc. 2021-02-16 /pmc/articles/PMC7940217/ /pubmed/33594813 http://dx.doi.org/10.1002/cam4.3779 Text en © 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Cancer Research Dai, Junzhu Teng, Lei Zhao, Liuyuan Zou, Huichao The combined analgesic effect of pregabalin and morphine in the treatment of pancreatic cancer pain, a retrospective study |
title | The combined analgesic effect of pregabalin and morphine in the treatment of pancreatic cancer pain, a retrospective study |
title_full | The combined analgesic effect of pregabalin and morphine in the treatment of pancreatic cancer pain, a retrospective study |
title_fullStr | The combined analgesic effect of pregabalin and morphine in the treatment of pancreatic cancer pain, a retrospective study |
title_full_unstemmed | The combined analgesic effect of pregabalin and morphine in the treatment of pancreatic cancer pain, a retrospective study |
title_short | The combined analgesic effect of pregabalin and morphine in the treatment of pancreatic cancer pain, a retrospective study |
title_sort | combined analgesic effect of pregabalin and morphine in the treatment of pancreatic cancer pain, a retrospective study |
topic | Clinical Cancer Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940217/ https://www.ncbi.nlm.nih.gov/pubmed/33594813 http://dx.doi.org/10.1002/cam4.3779 |
work_keys_str_mv | AT daijunzhu thecombinedanalgesiceffectofpregabalinandmorphineinthetreatmentofpancreaticcancerpainaretrospectivestudy AT tenglei thecombinedanalgesiceffectofpregabalinandmorphineinthetreatmentofpancreaticcancerpainaretrospectivestudy AT zhaoliuyuan thecombinedanalgesiceffectofpregabalinandmorphineinthetreatmentofpancreaticcancerpainaretrospectivestudy AT zouhuichao thecombinedanalgesiceffectofpregabalinandmorphineinthetreatmentofpancreaticcancerpainaretrospectivestudy AT daijunzhu combinedanalgesiceffectofpregabalinandmorphineinthetreatmentofpancreaticcancerpainaretrospectivestudy AT tenglei combinedanalgesiceffectofpregabalinandmorphineinthetreatmentofpancreaticcancerpainaretrospectivestudy AT zhaoliuyuan combinedanalgesiceffectofpregabalinandmorphineinthetreatmentofpancreaticcancerpainaretrospectivestudy AT zouhuichao combinedanalgesiceffectofpregabalinandmorphineinthetreatmentofpancreaticcancerpainaretrospectivestudy |